Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by AstraZeneca
< Previous
1
2
3
4
5
6
7
Next >
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
October 07, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
October 03, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
October 01, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
September 26, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
September 23, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
FLUMIST approved for self-administration in the US
September 20, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
September 18, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
September 16, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
September 15, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
September 13, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
September 09, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
September 08, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
September 03, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
August 16, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
August 15, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
July 29, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca’s H1 and Q2 2024 Financial Results
July 25, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
June 25, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
June 17, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
June 16, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
June 12, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
June 10, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
June 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
June 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
June 02, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
May 27, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
May 23, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
May 22, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
May 21, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
May 19, 2024
From
AstraZeneca
Via
Business Wire
Tickers
AZN
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.